-- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Bivamelagon Phase 2 trial met primary endpoint with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback